Havrix Junior (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Junior is indicated for the prevention of hepatitis A infection in children and adolescents.

• Active immunization of individuals aged 1 year and older who have not been previously exposed to hepatitis A virus.
• Inclusion in routine childhood vaccination schedules as recommended by national health authorities.
• Protection of travelers to regions where hepatitis A is endemic when administered according to travel‑related vaccination guidelines.
• Use in outbreak control settings to quickly establish herd immunity among susceptible pediatric populations.
• Administration prior to exposure in household contacts of hepatitis A cases, when clinically appropriate.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Headache or mild fatigue.
• Transient muscle or joint aches.

Serious

• Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, swelling of the face or throat, or hives.
• Neurological events such as Guillain‑Barré syndrome, although causality is rare.
• Persistent high fever lasting more than 48 hours.
• Unexplained bleeding or bruising.

Before administering Havrix Junior, healthcare providers should consider several precautionary factors to ensure safe use.

• Confirm that the child has no known severe allergy to any vaccine component, including algeldrate.
• Defer vaccination in individuals with a moderate or severe acute illness until recovery.
• Evaluate the need for vaccination in immunocompromised patients on a case‑by‑case basis.
• Review pregnancy status; the vaccine’s safety in pregnancy has not been established.
• Observe the patient for at least 15 minutes after injection for immediate hypersensitivity reactions.
• Document any previous hepatitis A vaccination to avoid unnecessary repeat dosing.

Havrix Junior may interact with other medicines or vaccines; awareness of these interactions helps optimize immunization schedules.

Avoid

• Concurrent administration with live‑attenuated vaccines (e.g., measles‑mumps‑rubella) without appropriate interval, as immune interference may reduce efficacy.
• Use in individuals receiving high‑dose immunoglobulin therapy within 2 weeks, which can neutralize the vaccine antigen.

Use with caution

• Simultaneous receipt of other inactivated vaccines (e.g., diphtheria‑tetanus‑pertussis) is generally acceptable but monitor for increased local reactions.
• Patients on immunosuppressive therapy may have a reduced antibody response; consider serologic testing after completion of the series.
• Antipyretics (acetaminophen, ibuprofen) can be used to manage mild post‑vaccination symptoms, but routine prophylactic use may blunt the immune response.